Merck appoints Baxter exec to fill chief financial officer role

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Merck appoints Baxter exec to fill chief financial officer role

Merck ($MRK) snagged a high-ranking member of Baxter's ($BAX) medical device outfit, bringing on Robert Davis as its new chief financial officer. Davis, who will replace 7-year veteran Peter Kellogg in the position, is currently Baxter's corporate vice president and president of its medical products business, and will take on the new role in the middle of May, according to Merck. Baxter, meanwhile, announced this week that it would be splitting its med tech and biopharmaceuticals businesses by the middle of 2015. Release

Merck
Robert Davis will be Merck's new CFO.


LabCorp
Glenn Eisenberg will join LabCorp as CFO.


Medical Devices & Diagnostics

> Labcorp ($LH) is bringing on Glenn Eisenberg to be its new CFO, beginning in June. More

> NeuroSigma appointed Carl Adams to be its chief financial officer and Craig Rostamian as its vice president of finance, overseeing planning and analysis. Item

> Biocept ($BIOC) has appointed Raaj Trivedi as vice president of commercial operations. Release

Biotech

> Merck KGaA said goodbye to R&D chief Annalisa Jenkins, appointed just last fall. Belén Garijo, CEO of the biopharma group, will temporarily take her place. More from the EuroBiotech Report

> Tobira Therapeutics appointed its chairman, Dr. Laurent Fischer, to be its new chief executive officer and Christopher Peetz as its chief financial officer. Release

> Osiris Therapeutics ($OSIR) brought on Therésa Dixon as its general manager of market access and reimbursement. Release

> Bio-Path Holdings appointed Ulrich Mueller as its chief operating officer. Release

> James Spies joined the Society of Interventional Radiology as the organization's president. Release

> Inergetics appointed Dr. Mark Wallace as a member of its medical and scientific advisory board. Release

> Adaptimmune brought on James Noble as its new CEO. Release

> BEAT BioTherapeutics appointed Dr. Sam Teichman as its chief medical officer. Release

> Claude Nivet joined Sirona Biochem as its new laboratory operations manager. Release

> ChemoCentryx ($CCXI) has appointed Dr. Anne-Marie Duliege to executive vice president, chief of strategic development and head of immuno-oncology, a newly created position within the company. Release

Kay Holcombe will be joining the Biotechnology Industry Organization (BIO) as senior vice president of science policy. Release

> Calithera Biosciences has appointed William Waddill as senior vice president and chief financial officer, effective April 1. Release

> Advaxis ($ADXS) has appointed Sara Bonstein to chief financial officer and senior vice president. Release

> Dr. Ryuji Ueno, cofounder and former chair, CEO and chief scientific officer of Sucampo Pharmaceuticals ($SCMP), is joining VLP Therapeutics as chair and chief medical officer. Release

> Robert Kaiko joined Cytogel Pharma as a scientific and clinical adviser. Release

Pharma

> AcelRx Pharmaceuticals ($ACRX) has appointed Timothy Morris as chief financial officer. Release

> Elorac has tapped Dr. Scott Phillips as senior vice president of scientific affairs. Release

CRO

> Quintiles ($Q) has appointed Stella Blackburn to vice president and global head of risk management for its real-world and late-phase research group. Release

> Ecron Acunova appointed Anders Malm as its managing director. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.